COMPLIANCE CERTIFICATE UNDER REGULATION 57(5) FOR THE QUARTER ENDED 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beryl Drugs Ltd has filed a non-applicability certificate under SEBI Regulation 57(5) for Q4 FY2026 (quarter ended March 31, 2026). The company states that this regulation does not apply because it has no non-convertible securities outstanding for which interest, dividend, or principal payments are due. The filing also includes Regulation 74(5) depository compliance certificate and Regulation 7(3) transfer facility compliance certificate. This is a routine quarterly compliance submission confirming the company has no debt securities or fixed-income instruments listed.
No direct impact on shareholders. This routine filing confirms the company has no listed debt securities, meaning bond or debenture holders should not expect any interest or principal payments. The stock remains equity-only listed on BSE.